Press Releases

26-06-2024

Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG

25-06-2024

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism

19-06-2024

Eckert & Ziegler and UJF Open State-of-the-Art Actinium-225 Production Facility

31-05-2024

Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA

24-05-2024

Eckert & Ziegler receives “Best Managed Companies Award”

14-05-2024

Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.

22-04-2024, 14:49 CEST (Ad hoc press release)

Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.

22-03-2024

Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023

21-03-2024

Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply

19-03-2024, 19:46 CET (Ad hoc press release)

Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.

19-03-2024

Eckert & Ziegler Completes Change of Legal Form to SE

28-02-2024

Eckert & Ziegler Extends Ga-68 Activities in Japan

31-01-2024

Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177

23-01-2024

Eckert & Ziegler and Full-Life Technologies Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals

08-01-2024

Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates